TITLE

Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature

AUTHOR(S)
Kawai, Y.; Ikegaya, S.; Hata, M.; Kawahito, M.; Imamura, S.; Yoshida, A.; Tsutani, H.; Ueda, T.
PUB. DATE
August 2001
SOURCE
Annals of Hematology;Aug2001, Vol. 80 Issue 8, p482
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reactivation of hepatitis B virus (HBV), especially after withdrawal of corticosteroids is a well-known complication during chemotherapy for lymphoma. The high mortality makes this complication one of the major obstacles to completing the standard treatment for lymphoma in HBV carriers. We report a 58-year-old Japanese male HBV carrier who developed fulminant hepatitis after chemotherapy with cyclophosphamide and doxorubicin. Lamivudine was introduced since his hepatitis was progressive under supportive treatment and showed an elevated level of HBV DNA. After initiation of lamivudine, HBV DNA decreased to be below the limit of detection within 3 weeks, and all chemical tests for liver function recovered to the normal level within 4 weeks, except for a slight elevation of total-bilirubin. There were no remarkable adverse effects observed. To the best of our knowledge, six cases of post-chemotherapeutic fulminant hepatitis including ours have been treated with lamivudine. A review of these cases indicated that lamivudine induced a prompt antiviral, biochemical, and clinical response. Lamivudine is highly recommended for post-chemotherapeutic fulminant hepatitis caused by reactivation of HBV.
ACCESSION #
15684766

 

Related Articles

  • Practice corner: should we screen all patients starting chemotherapy for chronic hepatitis B virus infection? McLachlan, Sue-Anne; De Cruz, Peter // Evidence Based Medicine;Feb2009, Vol. 14 Issue 1, p28 

    The article presents a study that aimed to find out the effect of screening the patients starting chemotherapy for chronic hepatitis B virus infection. It states that a 64 year-old Indian was admitted to the hospital with jaundice for eight months after finishing R-CHOP chemotherapy for diffuse...

  • Can determination of HBcAb titer be a surrogate for HBV DNA assay? Imawari, Michio // Journal of Gastroenterology;2000, Vol. 35 Issue 10, p796 

    Editorial. Discusses whether the determination of hepatitis B core antibody (HBcAb) titer can be a surrogate for hepatitis B virus (HBV) DNA assay. Findings on a patient with malignant lymphoma who developed severe hepatitis caused by HBV reactivation after chemotherapy.

  • Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ming-Shen Dai; Tsu-Yi Chao; Woei-Yau Kao; Rong-Yaun Shyu; Tan-Mei Liu // Annals of Hematology;Dec2004, Vol. 83 Issue 12, p769 

    Preemptive lamivudine in lymphoma patients undergoing intensive chemotherapy can effectively prevent chemotherapy-related HBV reactivation. Nevertheless, the safety profile after withdrawal of lamivudine and the impact of rituximab-containing chemotherapy on HBV reactivation has not been...

  • The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Yi-Fu He; Yu-Hong Li; Feng-Hua Wang; Wen-Qi Jiang; Rui-Hua Xu; Xiao-Fei Sun; Zhong-Jun Xia; Hui-Qiang Huang; Tong-Yu Lin; Li Zhang; Shi-Ping Bao; You-Jian He; Zhong-zhen Guan // Annals of Hematology;Jun2008, Vol. 87 Issue 6, p481 

    In rituximab-containing regimen for lymphoma, the role of lamivudine therapy has not been well established. Therefore, in this nonrandomized phase II clinical study, hepatitis B virus (HBV) carriers with B-cell lymphoma who received rituximab-containing regimen were treated with oral...

  • Lamivudine and Hepatitis B Reactivation. Chiun Hsu; Ann-Lii Cheng; Pei-Jer Chen; Loomba, Rohit; Pucino, Frank; Csako, Gyorgy // Annals of Internal Medicine;7/21/2009, Vol. 151 Issue 2, p141 

    Several letters to the editor are presented in response to articles in previous issues including a letter on an article related to the chemotherapy-induced hepatitis B virus (HBV) reactivation in patients with cancer who tested positive for HBV surface antigen, and another in response to the letter.

  • AIDE-MEMOIRE: for an effective approach to the immunization of health workers against hepatitis B.  // Immunization Newsletter;2009, Vol. 31 Issue 6, p6 

    The article offers information on the concepts and definitions of hepatitis B virus, a viral infection that can cause both acute and chronic disease and affects the liver.

  • Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Menne, Stephan; Tennant, Bud C. // Nature Medicine;Oct99, Vol. 5 Issue 10, p1125 

    The development of liver diseases in patients suffering from chronic hepatitis B infection is determined by the nature of the host immune response. Several factors have made this immune response difficult to study, but recently developed animal models will help clear the way.

  • Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Alexopoulos, C G; Vaslamatzis, M; Hatzidimitriou, G // British Journal of Cancer;9/1/99, Vol. 81 Issue 1, p69 

    To prospectively evaluate the prevalence of hepatitis B virus (HBV) positivity and study the evolution of HBV profile during cancer chemotherapy, serum HBV markers and liver biochemistry were determined in 1008 of 1402 (72%) cancer patients admitted in our Unit and in all 920 (91%) who received...

  • Antineoplastics.  // Reactions Weekly;1/8/2011, Issue 1333, p10 

    The article describes four cases of hepatitis B virus (HBV) reactivations that developed after the four patients received chemotherapy.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics